Filing Flows › Assembly Biosciences (ASMB) › Q3 2025
Assembly Biosciences (ASMB) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 10, 2025
Assembly Biosciences (ASMB) reported revenue of $10.8M for the third quarter 2025 (Q3 2025), +58% from a year earlier and +12% from the quarter before. Operating margin was -100.9%, net loss $9.2M (85.2% of revenue).
Assembly Biosciences, Q3 2025: revenue $10.8M (+58% year over year), operating margin -100.9%, net loss $9.2M, operating cash flow −$15.1M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $10.8M | +12% | +58% |
| Operating profit | −$10.9M | — | — |
| Net earnings | −$9.2M | — | — |
| Operating cash flow | −$15.1M | — | — |
What changed
Revenue was $10.8M in Q3 2025, up 58% year over year and up 12% from the previous quarter.
Operating costs exceeded revenue by $10.9M, an operating margin of -100.9%. Total costs grew 22% against revenue growth of 58%. The fastest-growing cost line was Research & development (+23%). The quarter ended with a net loss of $9.2M, narrower than the previous quarter's $10.2M loss.
Operating cash flow was −$15.1M. Non-cash charges added back $32K of depreciation and amortization and $1.7M of share-based compensation. Working capital and other items used $7.6M. Capital expenditures of $42K exceeded it, leaving free cash flow of −$15.2M.
Questions
What was Assembly Biosciences' revenue in the third quarter 2025?
Assembly Biosciences (ASMB) reported revenue of $10.8M for the third quarter 2025 (Q3 2025), +58% from a year earlier and +12% from the quarter before.
Was Assembly Biosciences profitable in the third quarter 2025?
Operating loss was $10.9M (-100.9% of revenue) and net loss $9.2M.